News & Insights

As evidence teams plan for 2026, expectations in rare diseases are shifting towards evidence that is carefully contextualised and clearly linked to decision-making needs. Recent guidance and industry commentary highlight the growing role of patient experience data, integrated real-world evidence, and earlier cross-functional planning, reinforcing that credibility comes from clarity and relevance rather than scale or complexity alone.

Daryl-Ashlee's reflections on her placement as part of her NHS Graduate Management Trainee Scheme at DHT.health collaborating with those who have a rare and underserved disease.

DHT.health launch Evidence and Insights programmes, a multi-country initiative built to capture patient voice, lived experience and outcomes in rare and underserved diseases.

DHT.health recognised among Grant Thornton’s Top 100 “Ones to Watch” in the UK Pharma Services Sector